Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHM-1092
- Development stage
- Preclinical
- Lead developer
- Chemia
- Modality
- Small Molecules
01
Overview
CHM-1092 is a small molecule drug candidate currently in the discovery or early development stages at Chemia, a biotechnology company that utilizes an AI-driven platform to discover and optimize natural product-inspired therapeutics. The compound is part of Chemia's internal pipeline, which focuses on translating complex natural product scaffolds into drug-like leads with improved pharmacological properties. While the specific biological target and primary clinical indication for CHM-1092 have not been publicly disclosed, Chemia's research programs are generally directed toward high-value therapeutic areas, including oncology and the treatment of multidrug-resistant infectious diseases.
Beyond the preview
Go deeper on CHM-1092.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHM-1092.